# Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

> **NCT05631249** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 40 (estimated)

## Conditions studied

- KRAS P.G12C
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Sotorasib 120Mg Tab

## Key facts

- **NCT ID:** NCT05631249
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2027-12-12
- **Final completion:** 2027-12-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05631249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05631249, "Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05631249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*